Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.44) by 25 percent. This is a 371.43 percent decrease over losses of $(0.07) per share
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced
Anticipates FDA PDUFA goal date in late 2021
If approved by the FDA for US market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters
WARREN, N.J., June